Alfonso Zulueta - Eli Lilly President
LLY Stock | USD 778.18 3.28 0.42% |
President
Mr. Alfonso Zulueta is the Senior Vice President, President Lilly International of the Company. He received a bachelor degree in economics from De La Salle University in the Philippines in 1982 and an MBA from the University of Virginia in 1987. In his 25 year career with Lilly, Zulueta has held several sales and marketing leadership positions in the United States before becoming general manager for the Philippines affiliate in 1995. He served as president of Asian operations prior to being promoted in 2008 to his current role as president and general manager of Lilly Japan, the company second largest market and affiliate behind only the U.S. since 2017.
Age | 57 |
Tenure | 7 years |
Professional Marks | MBA |
Address | Lilly Corporate Center, Indianapolis, IN, United States, 46285 |
Phone | 317 276 2000 |
Web | https://www.lilly.com |
Alfonso Zulueta Latest Insider Activity
Tracking and analyzing the buying and selling activities of Alfonso Zulueta against Eli Lilly stock is an integral part of due diligence when investing in Eli Lilly. Alfonso Zulueta insider activity provides valuable insight into whether Eli Lilly is net buyers or sellers over its current business cycle. Note, Eli Lilly insiders must abide by specific rules, including filing SEC forms every time they buy or sell Eli Lilly'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Alfonso Zulueta over six months ago Payment of 9674 shares by Alfonso Zulueta of Eli Lilly subject to Rule 16b-3 | ||
Alfonso Zulueta over six months ago Sale by Alfonso Zulueta of 7000 shares of Eli Lilly |
Eli Lilly Management Efficiency
The company has Return on Asset of 0.1188 % which means that on every $100 spent on assets, it made $0.1188 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.4844 %, implying that it generated $0.4844 on every 100 dollars invested. Eli Lilly's management efficiency ratios could be used to measure how well Eli Lilly manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to rise to 0.12 in 2024, whereas Return On Capital Employed is likely to drop 0.25 in 2024. At this time, Eli Lilly's Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 40.2 B in 2024, whereas Non Currrent Assets Other are likely to drop slightly above 2.9 B in 2024.Similar Executives
Showing other executives | PRESIDENT Age | ||
Wael Hashad | Seres Therapeutics | N/A | |
Henrik AncherJensen | Agilent Technologies | 59 | |
Thomas DesRosier | Seres Therapeutics | 63 | |
Craig Philips | Kineta Inc | 63 | |
Rodney Gonsalves | Agilent Technologies | 58 | |
Dominique Grau | Agilent Technologies | 65 | |
Samraat Raha | Agilent Technologies | 51 | |
Bruce Steel | Equillium | 50 | |
Patrick Kaltenbach | Agilent Technologies | 53 | |
Kevin Horgan | Seres Therapeutics | 58 | |
Michele Trucksis | Seres Therapeutics | 64 | |
Michael Tang | Agilent Technologies | 50 | |
Marcus Chapman | Seres Therapeutics | 47 | |
Bruce CFA | Equillium | 58 | |
Alicia Rodriguez | Agilent Technologies | N/A | |
Jacob Thaysen | Agilent Technologies | 49 | |
Rebecca Taub | Madrigal Pharmaceuticals | 66 | |
Marc Schneebaum | Madrigal Pharmaceuticals | 64 | |
Mark Doak | Agilent Technologies | 63 | |
Robert McMahon | Agilent Technologies | 55 | |
Wendy Rieder | Madrigal Pharmaceuticals | 46 |
Management Performance
Return On Equity | 0.48 | ||||
Return On Asset | 0.12 |
Eli Lilly And Leadership Team
Elected by the shareholders, the Eli Lilly's board of directors comprises two types of representatives: Eli Lilly inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Eli. The board's role is to monitor Eli Lilly's management team and ensure that shareholders' interests are well served. Eli Lilly's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Eli Lilly's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ralph Alvarez, Independent Director | ||
Jamere Jackson, Independent Director | ||
Johna Norton, Senior Vice President - Global Quality | ||
Juan Luciano, Lead Independent Director | ||
J Fyrwald, Independent Director | ||
Alfonso Zulueta, Senior Vice President and President - Emerging Markets business | ||
Anne White, Senior Vice President and Presidentident - Lilly Oncology | ||
Melissa Barnes, Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer | ||
Patrik Jonsson, Senior Vice President, Chief Customer Officer, President - Lilly Immunology, Lilly USA | ||
Karen Walker, Independent Director | ||
Ilya Yuffa, Senior Vice President and President of Lilly Bio-Medicines | ||
Enrique Conterno, Senior Vice President and President - Lilly Diabetes and President - Lilly USA | ||
Raul Alvarez, Independent Director | ||
Marschall Runge, Independent Director | ||
Anat JD, General VP | ||
Myles ONeill, Senior Vice President and President - Manufacturing Operations | ||
David Ricks, Senior Vice President and Presidentident - Lilly Bio-Medicines | ||
Daniel Skovronsky, Senior Vice President, Chief Scientific and Medical Officer, President - Lilly Research Laboratories | ||
Edgardo Hernandez, Senior Vice President and Presidentident - Manufacturing Operations | ||
Donald Zakrowski, Chief Finance | ||
Carolyn Bertozzi, Independent Director | ||
Erik Fyrwald, Independent Director | ||
Franklyn Prendergast, Independent Director | ||
Ellen Marram, Lead Independent Director | ||
Kathi Seifert, Independent Director | ||
Eric Dozier, Executive Diversity | ||
Joshua Smiley, Chief Financial Officer, Senior Vice President | ||
Anat Hakim, Senior Vice President, General Counsel, Secretary | ||
Fionnuala Walsh, Senior Vice President - Global Quality | ||
Alonzo Weems, Senior Vice President - Enterprise Risk Management, Chief Ethics and Compliance Officer | ||
Gabrielle Sulzberger, Independent Director | ||
Anat Ashkenazi, Chief Financial Officer, Senior Vice President | ||
Jeffrey Simmons, Senior Vice President and President - Elanco Animal Health | ||
John Lechleiter, Chairman, CEO and Pres | ||
Karen Horn, Independent Director | ||
Leigh Pusey, Senior Vice President - Corporate Affairs and Communications | ||
Darren Carroll, Senior Vice President - Corporate Business Development | ||
William Kaelin, Independent Director | ||
Jacob Naarden, Senior Vice President, Chief Executive Officer - Loxo Oncology at Lilly, President - Lilly Oncology | ||
Christi Shaw, Senior Vice President and President - Lilly Bio-Medicines | ||
Barton Peterson, Senior Vice President - Corporate Affairs and Communications | ||
Derica Rice, CFO, Executive VP of Global Services, Member of Operations Committee and Member of Policy and Strategy Committee | ||
Kimberly Johnson, Independent Director | ||
Michael Harrington, Executive Vice President, General Counsel | ||
David Hoover, Independent Director | ||
Maria Crowe, President - Manufacturing Operations | ||
Diogo Rau, Senior Vice President Chief Information and Digital Officer | ||
Jan Lundberg, Executive VP of Science and Technology and President of Lilly Research Laboratories | ||
Aarti Shah, Senior Vice President - Chief Information and Digital Officer | ||
Susan Mahony, Senior Vice President and President - Lilly Oncology | ||
Jackson Tai, Independent Director | ||
Michael Eskew, Independent Director | ||
Martin MIBS, VP Projects | ||
Katherine Baicker, Independent Director | ||
Stephen Fry, Senior Vice President - Human Resources and Diversity | ||
Michael Mason, Senior Vice President and President Lilly Diabetes |
Eli Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Eli Lilly a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.48 | ||||
Return On Asset | 0.12 | ||||
Profit Margin | 0.15 % | ||||
Operating Margin | 0.34 % | ||||
Current Valuation | 759.05 B | ||||
Shares Outstanding | 950.77 M | ||||
Shares Owned By Insiders | 0.16 % | ||||
Shares Owned By Institutions | 84.34 % | ||||
Number Of Shares Shorted | 5.42 M | ||||
Price To Earning | 54.92 X |
Eli Lilly Investors Sentiment
The influence of Eli Lilly's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Eli. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Eli Lilly's public news can be used to forecast risks associated with an investment in Eli. The trend in average sentiment can be used to explain how an investor holding Eli can time the market purely based on public headlines and social activities around Eli Lilly And. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Eli Lilly's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Eli Lilly's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Eli Lilly's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Eli Lilly.
Eli Lilly Implied Volatility | 31.31 |
Eli Lilly's implied volatility exposes the market's sentiment of Eli Lilly And stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Eli Lilly's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Eli Lilly stock will not fluctuate a lot when Eli Lilly's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Eli Lilly in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Eli Lilly's short interest history, or implied volatility extrapolated from Eli Lilly options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Eli Lilly And. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Complementary Tools for Eli Stock analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |
Is Eli Lilly's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eli Lilly. If investors know Eli will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eli Lilly listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.13 | Dividend Share 4.52 | Earnings Share 5.81 | Revenue Per Share 37.908 | Quarterly Revenue Growth 0.281 |
The market value of Eli Lilly And is measured differently than its book value, which is the value of Eli that is recorded on the company's balance sheet. Investors also form their own opinion of Eli Lilly's value that differs from its market value or its book value, called intrinsic value, which is Eli Lilly's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eli Lilly's market value can be influenced by many factors that don't directly affect Eli Lilly's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eli Lilly's value and its price as these two are different measures arrived at by different means. Investors typically determine if Eli Lilly is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eli Lilly's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.